MX336830B - Polipeptidos hibridos y quimericos del factor viii-fc, y metodos de uso de los mismos. - Google Patents

Polipeptidos hibridos y quimericos del factor viii-fc, y metodos de uso de los mismos.

Info

Publication number
MX336830B
MX336830B MX2012006347A MX2012006347A MX336830B MX 336830 B MX336830 B MX 336830B MX 2012006347 A MX2012006347 A MX 2012006347A MX 2012006347 A MX2012006347 A MX 2012006347A MX 336830 B MX336830 B MX 336830B
Authority
MX
Mexico
Prior art keywords
chimeric
factor viii
methods
hybrid polypeptides
cells
Prior art date
Application number
MX2012006347A
Other languages
English (en)
Other versions
MX2012006347A (es
Inventor
Alan J Bitonti
Jennifer A Dumont
Susan Low
Glenn Pierce
Alvin Luk
Haiyan Jiang
Byron Mckinney
Matt Ottmer
Jurg Sommer
Karen Nugent
Lian Li
Robert Peters
Original Assignee
Biogen Hemophilia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Hemophilia Inc filed Critical Biogen Hemophilia Inc
Publication of MX2012006347A publication Critical patent/MX2012006347A/es
Publication of MX336830B publication Critical patent/MX336830B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a uso de un polipéptido del Factor VIII (FVIII) de acción prolongada para la elaboración de un medicamento para reducir la incidencia de un episodio de sangrado en un sujeto humano en necesidad del mismo, en donde el medicamento está adaptado para ser administrable en dosis múltiples a en un intervalo de dosificación de tres días a siete días entre dos dosis, en donde cada una de las dosis múltiples provee de 25 IU/kg A 65 IU/kg del polipéptido del FVIII de acción prolongada, en donde el polipéptido del FVIII de acción prolongada es un híbrido monómero dímero del FVIIIFc que comprende una porción de FVIII y dos porciones de Fc, en donde una de las porciones de Fc se fusiona al extermo C-terminal de la cadena ligera de la porción del FVIII.
MX2012006347A 2009-12-06 2010-12-06 Polipeptidos hibridos y quimericos del factor viii-fc, y metodos de uso de los mismos. MX336830B (es)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US26707009P 2009-12-06 2009-12-06
US28505409P 2009-12-09 2009-12-09
US30159210P 2010-02-04 2010-02-04
US36306510P 2010-07-09 2010-07-09
US37311310P 2010-08-12 2010-08-12
US41092910P 2010-11-07 2010-11-07
US41967610P 2010-12-03 2010-12-03
PCT/US2010/059136 WO2011069164A2 (en) 2009-12-06 2010-12-06 Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof

Publications (2)

Publication Number Publication Date
MX2012006347A MX2012006347A (es) 2012-10-03
MX336830B true MX336830B (es) 2016-02-03

Family

ID=44115536

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2016000039A MX353233B (es) 2009-12-06 2010-12-06 Polipéptidos híbridos y quiméricos del factor viii-fc, y métodos de uso de los mismos.
MX2018000089A MX382693B (es) 2009-12-06 2010-12-06 Polipéptidos híbridos y quiméricos del factor viii-fc, y métodos de uso de los mismos.
MX2012006347A MX336830B (es) 2009-12-06 2010-12-06 Polipeptidos hibridos y quimericos del factor viii-fc, y metodos de uso de los mismos.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2016000039A MX353233B (es) 2009-12-06 2010-12-06 Polipéptidos híbridos y quiméricos del factor viii-fc, y métodos de uso de los mismos.
MX2018000089A MX382693B (es) 2009-12-06 2010-12-06 Polipéptidos híbridos y quiméricos del factor viii-fc, y métodos de uso de los mismos.

Country Status (30)

Country Link
US (5) US9050318B2 (es)
EP (4) EP2506868B1 (es)
JP (8) JP5903048B2 (es)
KR (1) KR101770849B1 (es)
CN (1) CN102791285A (es)
AU (6) AU2010325787B2 (es)
BR (1) BR112012013502A2 (es)
CA (2) CA3121739A1 (es)
CO (1) CO6561782A2 (es)
CY (2) CY1119919T1 (es)
DK (1) DK2506868T3 (es)
EA (2) EA025416B1 (es)
ES (2) ES2880038T3 (es)
HR (2) HRP20180135T1 (es)
HU (1) HUE036233T2 (es)
IL (2) IL220204B (es)
LT (1) LT2506868T (es)
ME (1) ME02964B (es)
MX (3) MX353233B (es)
MY (1) MY159135A (es)
NO (1) NO2506868T3 (es)
NZ (2) NZ600709A (es)
PL (2) PL2506868T3 (es)
PT (2) PT3326643T (es)
RS (1) RS56957B1 (es)
SG (3) SG10201907152YA (es)
SI (1) SI2506868T1 (es)
SM (1) SMT201800099T1 (es)
WO (1) WO2011069164A2 (es)
ZA (1) ZA201204874B (es)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6263355A (ja) * 1985-09-13 1987-03-20 Hitachi Ltd バツテリバツクアツプｒａｍのチエツク方法
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
ES2610356T3 (es) 2009-02-03 2017-04-27 Amunix Operating Inc. Polipéptidos recombinantes extendidos y composiciones que comprenden los mismos
EP3222287A1 (en) 2009-08-24 2017-09-27 Amunix Operating Inc. Coagulation factor ix compositions and methods of making and using same
EA025416B1 (ru) * 2009-12-06 2016-12-30 Байоджен Хемофилия Инк. Способ предотвращения или лечения эпизодов кровотечений с использованием химерного полипептида фактора viii длительного действия
TW201217527A (en) 2010-07-09 2012-05-01 Biogen Idec Hemophilia Inc Processable single chain molecules and polypeptides made using same
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
MX2013003681A (es) 2010-10-01 2013-11-20 Moderna Therapeutics Inc Ácidos nucleicos manipulados y métodos de uso de los mismos.
CA2930801C (en) 2010-11-05 2019-05-28 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase
DE12722942T1 (de) 2011-03-31 2021-09-30 Modernatx, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
WO2012170969A2 (en) 2011-06-10 2012-12-13 Biogen Idec Ma Inc. Pro-coagulant compounds and methods of use thereof
TWI687226B (zh) * 2011-07-08 2020-03-11 美商百歐維拉提夫治療公司 因子ｖｉｉｉ嵌合及雜交多肽，及其使用方法
WO2013016454A1 (en) * 2011-07-25 2013-01-31 Biogen Idec Hemophilia Inc. Assays to monitor bleeding disorders
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
SI3682905T1 (sl) 2011-10-03 2022-04-29 Modernatx, Inc. Modificirani nukleozidi, nukleotidi in nukleinske kisline ter njihove uporabe
US20130156849A1 (en) 2011-12-16 2013-06-20 modeRNA Therapeutics Modified nucleoside, nucleotide, and nucleic acid compositions
CN111499760A (zh) * 2012-01-12 2020-08-07 比奥贝拉蒂治疗公司 嵌合因子viii多肽及其用途
CN104254614A (zh) * 2012-01-12 2014-12-31 比奥根艾迪克Ma公司 降低经受因子viii疗法的个体中针对因子viii的免疫原性的方法
DK2822577T3 (en) 2012-02-15 2019-04-01 Bioverativ Therapeutics Inc RECOMBINANT FACTOR VIII PROTEINS
ES2771208T3 (es) * 2012-02-15 2020-07-06 Bioverativ Therapeutics Inc Composiciones de factor VIII y métodos de preparación y uso de las mismas
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
HK1206601A1 (en) 2012-04-02 2016-01-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
EP3521321B1 (en) 2012-04-11 2020-11-04 Bioverativ Therapeutics Inc. Methods of detecting glycosaminoglycans
CA2875246A1 (en) 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Procoagulant compounds
US10202595B2 (en) 2012-06-08 2019-02-12 Bioverativ Therapeutics Inc. Chimeric clotting factors
EP2870250B2 (en) 2012-07-06 2022-06-29 Bioverativ Therapeutics Inc. Cell line expressing single chain factor viii polypeptides and uses thereof
SI2882450T1 (sl) * 2012-07-11 2020-02-28 Bioverativ Therapeutics Inc. Kompleks faktorja VIII z XTEN in s proteinom von Willebrandovega faktorja in njegove uporabe
HK1212882A1 (zh) 2012-07-25 2016-06-24 Bioverativ Therapeutics Inc. 血液因子的監測分析及其用途
AU2013331000B2 (en) 2012-10-18 2018-04-19 Bioverativ Therapeutics Inc. Methods of using a fixed dose of a clotting factor
EP3446700A1 (en) * 2012-10-30 2019-02-27 Bioverativ Therapeutics Inc. Methods of using fviii polypeptide
SI2922554T1 (sl) 2012-11-26 2022-06-30 Modernatx, Inc. Terminalno modificirana RNA
US10717965B2 (en) 2013-01-10 2020-07-21 Gloriana Therapeutics, Inc. Mammalian cell culture-produced neublastin antibodies
WO2014127215A1 (en) 2013-02-15 2014-08-21 Biogen Idec Ma Inc. Optimized factor viii gene
US9090697B2 (en) * 2013-03-15 2015-07-28 Bayer Healthcare Llc Methods for treating bleeding disorders
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP2968477B1 (en) 2013-03-15 2019-12-04 Bioverativ Therapeutics Inc. Factor viii polypeptide formulations
WO2014190305A2 (en) 2013-05-24 2014-11-27 Biogen Idec Ma Inc. Anti-gpiib/iiia antibodies or uses thereof
TW201536811A (zh) * 2013-05-31 2015-10-01 Biogen Idec Inc 嵌合ｆｖｉｉ－ｘｔｅｎ分子及其用途
GEAP201914559A (en) * 2013-06-20 2019-02-11 Baxalta GmbH Method and system for providing a pharmacokinetic drug dosing regime
HK1223302A1 (zh) * 2013-06-28 2017-07-28 Bioverativ Therapeutics Inc. 具有xten的凝血酶可裂解连接子和其用途
US20160229903A1 (en) * 2013-06-28 2016-08-11 Biogen Ma Inc. Thrombin cleavable linker
CA3012994C (en) 2013-07-31 2020-10-20 Rinat Neuroscience Corp. Engineered polypeptide conjugates
EP3033097B1 (en) 2013-08-14 2021-03-10 Bioverativ Therapeutics Inc. Factor viii-xten fusions and uses thereof
EP4108254A1 (en) 2013-08-14 2022-12-28 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
US10611794B2 (en) 2013-09-25 2020-04-07 Bioverativ Therapeutics Inc. On-column viral inactivation methods
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
SG11201602503TA (en) 2013-10-03 2016-04-28 Moderna Therapeutics Inc Polynucleotides encoding low density lipoprotein receptor
WO2015070014A1 (en) 2013-11-08 2015-05-14 Biogen Idec Ma Inc. Procoagulant fusion compound
WO2015085276A1 (en) * 2013-12-06 2015-06-11 Biogen Idec Ma Inc. Population pharmacokinetics tools and uses thereof
EP3083933B1 (en) 2013-12-20 2026-01-21 Biogen MA Inc. Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality
NZ721544A (en) 2014-01-10 2022-10-28 Bioverativ Therapeutics Inc Factor viii chimeric proteins and uses thereof
WO2015120056A1 (en) 2014-02-04 2015-08-13 Biogen Ma Inc. Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications
WO2015148454A1 (en) * 2014-03-28 2015-10-01 Asklepios Biopharmaceutical, Inc. Optimized and modified factor viii genes for gene therapy
KR20160145790A (ko) 2014-04-25 2016-12-20 리나트 뉴로사이언스 코프. 약물이 고도로 로딩된 항체-약물 접합체
EP3160478A4 (en) 2014-06-30 2018-05-16 Bioverativ Therapeutics Inc. Optimized factor ix gene
CA2964317C (en) 2014-10-14 2021-10-05 Halozyme, Inc. Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
MA40835A (fr) 2014-10-23 2017-08-29 Biogen Ma Inc Anticorps anti-gpiib/iiia et leurs utilisations
MA40861A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Anticorps anti-glycoprotéines iib/iiia
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
TWI741992B (zh) 2015-08-03 2021-10-11 美商百歐維拉提夫治療公司 因子ｉｘ融合蛋白以及其製備及使用方法
WO2017070167A1 (en) 2015-10-20 2017-04-27 The University Of North Carolina At Chapel Hill Methods and compositions for modified factor ix fusion proteins
LT3411478T (lt) 2016-02-01 2022-09-26 Bioverativ Therapeutics Inc. Optimizuoti viii faktoriaus genai
JP6942721B2 (ja) 2016-04-15 2021-09-29 バクスアルタ インコーポレイティッド 薬物動態学的薬物投与計画を提供する方法及び装置
TW201739448A (zh) * 2016-05-06 2017-11-16 安成生物科技股份有限公司 用於治療及/或預防血液相關疾病之方法及配方
US11046749B2 (en) 2016-06-24 2021-06-29 Mogam Institute For Biomedical Research Chimera protein comprising FVIII and vWF factors, and use thereof
KR20190077306A (ko) 2016-08-05 2019-07-03 메디뮨 엘엘씨 항-o2 항체 및 이의 용도
CN106279437B (zh) * 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
CN107759697B (zh) 2016-08-19 2023-03-24 安源医药科技（上海）有限公司 制备融合蛋白的方法
JP7160484B2 (ja) 2016-10-19 2022-10-25 メディミューン，エルエルシー 抗ｏ１抗体およびその使用
MX2019006444A (es) 2016-12-02 2019-10-30 Bioverativ Therapeutics Inc Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos.
CN110520149A (zh) 2016-12-02 2019-11-29 比奥维拉迪维治疗股份有限公司 诱导对凝血因子的免疫耐受性的方法
CN108239151B (zh) * 2016-12-23 2020-07-03 海门晟斯生物制药有限公司 重组单链人FVIII-Fc融合蛋白及其应用
US10896749B2 (en) * 2017-01-27 2021-01-19 Shire Human Genetic Therapies, Inc. Drug monitoring tool
CA3051862A1 (en) 2017-01-31 2018-08-09 Bioverativ Therapeutics Inc. Factor ix fusion proteins and methods of making and using same
MA52630B1 (fr) 2018-05-18 2025-07-31 Bioverativ Therapeutics Inc. Procédés de traitement de l'hémophilie a
MA52783A (fr) 2018-06-05 2021-04-14 Amgen Inc Modulation de la phagocytose cellulaire dépendant de l'anticorps
MA53603A (fr) 2018-09-11 2021-07-21 Amgen Inc Procédés de modulation de la cytotoxicité à médiation cellulaire dépendante des anticorps
WO2020086408A1 (en) 2018-10-26 2020-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A high-yield perfusion-based transient gene expression bioprocess
CN113396223A (zh) 2018-12-06 2021-09-14 比奥维拉迪维治疗股份有限公司 表达因子ix的慢病毒载体的用途
AU2020298233A1 (en) 2019-06-19 2022-01-20 Bioverativ Therapeutics Inc. Recombinant factor VIII-Fc for treating hemophilia and low bone mineral density
TW202126284A (zh) 2019-09-30 2021-07-16 美商百歐維拉提夫治療公司 慢病毒載體配製物
CA3183557A1 (en) 2020-06-24 2021-12-30 Bioverativ Therapeutics Inc. Methods for the removal of free factor viii from preparations of lentiviral vectors modified to express said protein
JP2025515356A (ja) * 2022-04-28 2025-05-14 ジョイント・ストック・カンパニー “バイオキャド” Ｆｖｉｉｉ－ｂｄｄおよび異種シグナルペプチドに基づく融合タンパク質をコードする単離された核酸
CN114989307B (zh) * 2022-05-11 2023-08-01 华兰生物工程股份有限公司 一种重组人凝血因子Ⅷ-Fc融合蛋白及制备方法

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235881A (en) * 1978-12-04 1980-11-25 Cort Joseph H Method for producing high potency factor VIII
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4868112A (en) 1985-04-12 1989-09-19 Genetics Institute, Inc. Novel procoagulant proteins
KR910006424B1 (ko) 1985-08-21 1991-08-24 인코텍스 비.브이 편성브리프(brief) 제조방법
EP0253870B1 (en) 1986-01-03 1993-03-31 Genetics Institute, Inc. Method for producing factor viii:c-type proteins
US5595886A (en) 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US5543502A (en) 1986-06-24 1996-08-06 Novo Nordisk A/S Process for producing a coagulation active complex of factor VIII fragments
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
CA1331157C (en) 1987-04-06 1994-08-02 Randal J. Kaufman Method for producing factor viii:c-type proteins
US6060447A (en) 1987-05-19 2000-05-09 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
US5171844A (en) 1987-06-12 1992-12-15 Gist-Brocades N.W. Proteins with factor viii activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
DE3720246A1 (de) 1987-06-19 1988-12-29 Behringwerke Ag Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet
FR2619314B1 (fr) 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
US4994371A (en) 1987-08-28 1991-02-19 Davie Earl W DNA preparation of Christmas factor and use of DNA sequences
US5004803A (en) 1988-11-14 1991-04-02 Genetics Institute, Inc. Production of procoagulant proteins
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
CA2078721A1 (en) 1991-09-24 1993-03-25 Hiroshi Yonemura Process for preparing human coagulation factor viii protein complex
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5859204A (en) 1992-04-07 1999-01-12 Emory University Modified factor VIII
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US6376463B1 (en) 1992-04-07 2002-04-23 Emory University Modified factor VIII
US5563045A (en) 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
US6818439B1 (en) 1994-12-30 2004-11-16 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders
SE9503380D0 (sv) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
US6458563B1 (en) 1996-06-26 2002-10-01 Emory University Modified factor VIII
CA2225189C (en) 1997-03-06 2010-05-25 Queen's University At Kingston Canine factor viii gene, protein and methods of use
ATE336514T1 (de) 2000-02-11 2006-09-15 Merck Patent Gmbh Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen
ES2529300T3 (es) * 2000-04-12 2015-02-18 Novozymes Biopharma Dk A/S Proteínas de fusión de albúmina
CN1592632A (zh) * 2001-02-05 2005-03-09 诺沃挪第克健康护理股份公司 Ⅶ因子多肽和ⅷ因子多肽的联合应用
ES2425738T3 (es) 2001-12-21 2013-10-17 Human Genome Sciences, Inc. Proteínas de fusión de la albúmina
US7041635B2 (en) 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
EP1444986A1 (en) * 2003-02-07 2004-08-11 Aventis Behring GmbH Pharmaceutical preparation for the improved treatment of blood-clotting disorders
ES2333598T5 (es) 2003-05-06 2013-09-04 Biogen Idec Hemophilia Inc Proteinas quimericas del factor de coagulacion fc para tratar la hemofilia.
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
MXPA05013789A (es) 2003-06-19 2006-06-27 Tanox Inc Composiciones y metodos para tratar los desordenes relacionados con la coagulacion.
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
US7632921B2 (en) 2004-11-12 2009-12-15 Bayer Healthcare Llc Site-directed modification of FVIII
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
EP1996220B2 (en) 2006-03-06 2023-08-16 Amunix Operating Inc. Unstructured recombinant polymers and uses thereof
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
BRPI0708832A2 (pt) * 2006-03-31 2011-06-14 Baxter Int construÇço proteinÁcea
AU2007338298B2 (en) 2006-12-22 2013-02-07 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life
CA2695374A1 (en) 2007-08-15 2009-02-19 Amunix, Inc. Compositions and methods for modifying properties of biologically active polypeptides
RU2573587C2 (ru) * 2008-02-27 2016-01-20 Ново Нордиск А/С Конъюгированные молекулы фактора viii
US8800831B2 (en) 2009-08-19 2014-08-12 Larry A. Gray Multi-purpose rack and method thereof
ES2610356T3 (es) 2009-02-03 2017-04-27 Amunix Operating Inc. Polipéptidos recombinantes extendidos y composiciones que comprenden los mismos
EP2411024A4 (en) * 2009-03-24 2013-02-27 Bayer Healthcare Llc Variants of factor viii and associated methods of use
GB0908515D0 (en) 2009-05-18 2009-06-24 Apitope Technology Bristol Ltd Peptide
EA025416B1 (ru) 2009-12-06 2016-12-30 Байоджен Хемофилия Инк. Способ предотвращения или лечения эпизодов кровотечений с использованием химерного полипептида фактора viii длительного действия
TWI687226B (zh) * 2011-07-08 2020-03-11 美商百歐維拉提夫治療公司 因子ｖｉｉｉ嵌合及雜交多肽，及其使用方法
CN104254614A (zh) * 2012-01-12 2014-12-31 比奥根艾迪克Ma公司 降低经受因子viii疗法的个体中针对因子viii的免疫原性的方法
EP2968477B1 (en) * 2013-03-15 2019-12-04 Bioverativ Therapeutics Inc. Factor viii polypeptide formulations
JP6083911B2 (ja) 2014-12-19 2017-02-22 花王株式会社 吸収性物品

Also Published As

Publication number Publication date
JP6641340B2 (ja) 2020-02-05
EP3906937A1 (en) 2021-11-10
AU2017268648B2 (en) 2019-01-31
SG10201907152YA (en) 2019-09-27
JP5903048B2 (ja) 2016-04-13
MX2012006347A (es) 2012-10-03
WO2011069164A3 (en) 2011-07-28
KR20120129882A (ko) 2012-11-28
AU2021202912A1 (en) 2021-06-03
US20130274194A1 (en) 2013-10-17
MX353233B (es) 2018-01-08
JP2017025098A (ja) 2017-02-02
EP2506868A2 (en) 2012-10-10
AU2016213822A1 (en) 2016-09-01
ZA201204874B (en) 2016-06-29
KR101770849B1 (ko) 2017-09-05
US20130108629A1 (en) 2013-05-02
AU2010325787A1 (en) 2012-07-12
JP2020019821A (ja) 2020-02-06
JP6062459B2 (ja) 2017-01-18
AU2010325787A2 (en) 2013-06-06
CA2782424A1 (en) 2011-06-09
AU2017268648A1 (en) 2017-12-21
DK2506868T3 (da) 2018-01-29
EP2506868A4 (en) 2013-07-24
EP3326643A1 (en) 2018-05-30
PL2506868T3 (pl) 2018-06-29
EA025416B1 (ru) 2016-12-30
EP3326643B1 (en) 2021-04-07
US20160199455A1 (en) 2016-07-14
BR112012013502A2 (pt) 2017-01-10
ES2659888T3 (es) 2018-03-19
SG181130A1 (en) 2012-07-30
WO2011069164A2 (en) 2011-06-09
JP2018024706A (ja) 2018-02-15
EP4382170A3 (en) 2024-09-04
AU2016213822B2 (en) 2017-08-31
HUE036233T2 (hu) 2018-06-28
NZ703153A (en) 2015-02-27
SG10201408049SA (en) 2015-02-27
EA038618B1 (ru) 2021-09-23
EA201691109A1 (ru) 2017-01-30
CA3121739A1 (en) 2011-06-09
SMT201800099T1 (it) 2018-03-08
JP6385410B2 (ja) 2018-09-05
NO2506868T3 (es) 2018-04-14
CY1124888T1 (el) 2023-01-05
JP2023071969A (ja) 2023-05-23
HRP20180135T1 (hr) 2018-04-06
CA2782424C (en) 2021-07-27
JP7244688B2 (ja) 2023-03-22
IL220204B (en) 2018-08-30
EA201290443A1 (ru) 2013-06-28
JP2015083608A (ja) 2015-04-30
EP4382170A2 (en) 2024-06-12
ME02964B (me) 2018-07-20
MY159135A (en) 2016-12-15
CN102791285A (zh) 2012-11-21
AU2010325787B2 (en) 2016-05-12
JP2025083451A (ja) 2025-05-30
RS56957B1 (sr) 2018-05-31
AU2021202912B2 (en) 2024-08-01
IL260769B (en) 2020-03-31
NZ600709A (en) 2015-01-30
SI2506868T1 (en) 2018-04-30
IL220204A0 (en) 2012-07-31
HK1253887A1 (en) 2019-07-05
CY1119919T1 (el) 2018-06-27
CO6561782A2 (es) 2012-11-15
US9050318B2 (en) 2015-06-09
JP2022051964A (ja) 2022-04-01
HRP20211010T1 (hr) 2021-09-17
AU2019202969A1 (en) 2019-05-16
LT2506868T (lt) 2018-02-26
PT2506868T (pt) 2018-02-23
AU2010325787A8 (en) 2012-07-19
PT3326643T (pt) 2021-07-12
US9241978B2 (en) 2016-01-26
JP2013512678A (ja) 2013-04-18
AU2024227757A1 (en) 2024-11-21
EP2506868B1 (en) 2017-11-15
MX382693B (es) 2025-03-13
PL3326643T3 (pl) 2021-10-25
US20220265780A1 (en) 2022-08-25
US20190262429A1 (en) 2019-08-29
ES2880038T3 (es) 2021-11-23
US11266720B2 (en) 2022-03-08

Similar Documents

Publication Publication Date Title
MY159135A (en) Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
MX2020009702A (es) Polipeptidos de factor ix y metodos para usarlos.
MY180714A (en) Factor viii chimeric and hybrid polypeptides, and methods of use thereof
PH12018501839A1 (en) St2l antagonists and methods of use
HK1213521A1 (zh) Fix多肽的應用
MX2012007710A (es) Alfa-amilasas.
PH12012500862B1 (en) Il-17a antagonists
MX2011012623A (es) Construcciones de casb7439.
GB0818080D0 (en) Immunogenic peptides
HK1185266A (zh) 因子ix多肽及其使用方法
EA202092566A1 (ru) Фактор ix полипептиды и способы их использования
UA35660U (en) Use of antihomotoxic preparations as cytoprotectors

Legal Events

Date Code Title Description
FG Grant or registration